Strongyloides stercoralis infection

BMJ (Online)

Volumn 347, Issue 7919, 2013, Pages

  Greaves, Daniel ^a   Coggle, Sian ^a   Pollard, Christopher ^b   Aliyu, Sani H ^a   Moore, Elinor M ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTIBIOTIC AGENT; BENZIMIDAZOLE; IMMUNOGLOBULIN G; IVERMECTIN; PARASITE ANTIBODY;

ABDOMINAL DISTENSION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ANTIBIOTIC THERAPY; ANTIBODY DETECTION; CHEST TIGHTNESS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERANCE; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; FECES ANALYSIS; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; LOIASIS; NEMATODE LIFE CYCLE STAGE; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PARASITE CULTIVATION; PARASITE LOAD; PARASITE SERODIAGNOSIS; PARASITE VIRULENCE; PATIENT REFERRAL; PRIORITY JOURNAL; REVIEW; SEPSIS; SIDE EFFECT; STRONGYLOIDES HYPERINFECTION SYNDROME; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; SYMPTOMATOLOGY; TRAVEL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIPARASITIC AGENTS; HUMANS; IVERMECTIN; LIFE CYCLE STAGES; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; SUPERINFECTION;

EID: 84881250158     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4610     Document Type: Review

References (41)

1. World Health Organization. Neglected tropical diseases -strongyloidiasis. 2013. www.who.int/neglected-diseases/diseases/strongyloidiasis/en/.
2. Valerio L, Roure S, Fernandez-Rivas G, Basile L, Martinez-Cuevas O, Ballesteros AL, et al. Strongyloides stercoralis, the hidden worm. Epidemiological and clinical characteristics of 70 cases diagnosed in the North Metropolitan Area of Barcelona, Spain, 2003-2012. Trans R Soc Trop Med Hyg 2013;107:465-70.
3. Prendki V, Fenaux P, Durand R, Thellier M, Bouchaud O. Strongyloidiasis in man 75 years after initial exposure. Emerg Infect Dis 2011;17:931-2.
4. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001;33:1040-7.
5. HM Government. Home Office immigration statistics January to March 2013. www.gov. uk/government/publications/immigration-statistics-january-to-march- 2013/immigrationstatistics-january-to-march-2013.
6. Gyorkos TW, Genta RM, Viens P, MacLean JD. Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada. Am J Epidemiol 1990;132:257-64.
7. Posey DL, Blackburn BG, Weinberg M, Flagg EW, Ortega L, Wilson M, et al. High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. Clin Infect Dis 2007;45:1310-5.
8. Sorvillo F, Mori K, Sewake W, Fishman L. Sexual transmission of Strongyloides stercoralis among homosexual men. Br J Vener Dis 1983;59:342.
9. Hamilton KW, Abt PL, Rosenbach MA, Bleicher MB, Levine MS, Mehta J, et al. Donor-derived Strongyloides stercoralis infections in renal transplant recipients. Transplantation 2011;91:1019-24.
10. Zeehaida M, Zairi NZ, Rahmah N, Maimunah A, Madihah B. Strongyloides stercoralis in common vegetables and herbs in Kota Bharu, Kelantan, Malaysia. Trop Biomed 2011;28:188-93.
11. Gonzalez A, Gallo M, Valls ME, Munoz J, Puyol L, Pinazo MJ, et al. Clinical and epidemiological features of 33 imported Strongyloides stercoralis infections. Trans R Soc Trop Med Hyg 2010;104:613-6.
12. Sims H, Erber WN. Investigation of an incidental finding of eosinophilia. BMJ 2011;342:d2670.
13. Jones CA, Abadie SH. Studies in human strongyloidiasis. II. A comparison of the efficiency of diagnosis by examination of feces and duodenal fluid. Am J Clin Pathol 1954;24:1154-8.
14. Boulware DR, Stauffer WM 3rd, Walker PF. Hypereosinophilic syndrome and mepolizumab. N Engl J Med 2008;358:2839; author reply 39-40.
15. Van Doorn HR, Koelewijn R, Hofwegen H, Gilis H, Wetsteyn JC, Wismans PJ, et al. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol 2007;45:438-42.
16. Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Trans R Soc Trop Med Hyg 2007;101:1163-5.
17. Wurtz R, Mirot M, Fronda G, Peters C, Kocka F. Short report: gastric infection by Strongyloides stercoralis. Am J Trop Med Hyg 1994;51:339-40.
18. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 2004;17:208-17.
19. Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009;49:1411-23.
20. Dulley FL, Costa S, Cosentino R, Gamba C, Saboya R. Strongyloides stercoralis hyperinfection after allogeneic stem cell transplantation. Bone Marrow Transplant 2009;43:741-2.
21. Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007;7:266-81.
22. Terashima A, Alvarez H, Tello R, Infante R, Freedman DO, Gotuzzo E. Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection. Int J Infect Dis 2002;6:28-30.
23. Gotuzzo E, Terashima A, Alvarez H, Tello R, Infante R, Watts DM, et al. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am J Trop Med Hyg 1999;60:146-9.
24. Assefa S, Erko B, Medhin G, Assefa Z, Shimelis T. Intestinal parasitic infections in relation to HIV/AIDS status, diarrhea and CD4 T-cell count. BMC Infect Dis 2009;9:155.
25. Greaves D, Gouliouris T, O'Donovan M, Craig JI, Torok ME. Strongyloides stercoralis hyperinfection in a patient treated for multiple myeloma. Br J Haematol 2012;158:2.
26. Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, Nilganuwong S, Karuphong E, et al. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis 2011;5:e1044.
27. Zaha O, Hirata T, Uchima N, Kinjo F, Saito A. Comparison of anthelmintic effects of two doses of ivermectin on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody. J Infect Chemother 2004;10:348-51.
28. Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, Sanchez-Sanchez P, Matogo-Oyana J, Rodriguez-Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004;5:2615-9.
29. Gann PH, Neva FA, Gam AA. A randomized trial of single-and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994;169:1076-9.
30. Datry A, Hilmarsdottir I, Mayorga-Sagastume R, Lyagoubi M, Gaxotte P, Biligui S, et al. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg 1994;88:344-5.
31. Marti H, Haji HJ, Savioli L, Chwaya HM, Mgeni AF, Ameir JS, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996;55:477-81.
32. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997;350:18-22.
33. Nontasut P, Muennoo C, Sa-nguankiat S, Fongsri S, Vichit A. Prevalence of strongyloides in Northern Thailand and treatment with ivermectin vs albendazole. Southeast Asian J Trop Med Public Health 2005;36:442-4.
34. Mejia R, Nutman TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 2012;25:458-63.
35. Chiodini PL, Reid AJ, Wiselka MJ, Firmin R, Foweraker J. Parenteral ivermectin in Strongyloides hyperinfection. Lancet 2000;355:43-4.
36. Lichtenberger P, Rosa-Cunha I, Morris M, Nishida S, Akpinar E, Gaitan J, et al. Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin. Transpl Infect Dis 2009;11:137-42.
37. Biggs BA, Caruana S, Mihrshahi S, Jolley D, Leydon J, Chea L, et al. Management of chronic strongyloidiasis in immigrants and refugees: is serologic testing useful? Am J Trop Med Hyg 2009;80:788-91.
38. Kobayashi J, Sato Y, Toma H, Takara M, Shiroma Y. Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. Diagn Microbiol Infect Dis 1994;18:19-23.
39. Loutfy MR, Wilson M, Keystone JS, Kain KC. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg 2002;66:749-52.
40. Nuesch R, Zimmerli L, Stockli R, Gyr N, Christoph Hatz FR. Imported strongyloidosis: a longitudinal analysis of 31 cases. J Travel Med 2005;12:80-4.
41. HM Government. Foreign and Commonwealth Office. Travel advice by country -Thailand. 2013. www.fco.gov.uk/en/travel-and-living-abroad/travel-advice-by- country/asia-oceania/thailand/.